Cannabis

New federal hemp restrictions and rising rescheduling momentum are reshaping the outlook for cannabis ETFs and U.S. operators.

Federal cannabis rescheduling could reshape U.S. markets. Here’s what it means for businesses, policy, and cannabis ETFs eyeing new growth opportunities.

Cannabis rescheduling hearings face delays and controversies, reflecting reform complexities and challenges for U.S. advocates.

Looking at which ETFs had the poorest returns last year.

Shifting political tides and GOP support could drive cannabis growth, offering investment opportunities amid evolving U.S. policies.

The upcoming November election in the US could be a pivotal moment for cannabis laws across several states.

Tap into the future of mental health treatment with psychedelic ETFs, offering diversified, long-term growth opportunities in an emerging healthcare sector.

2024 represents a historical moment where both Republican and Democratic Presidential candidates have embraced some level of substantial cannabis reform.

The recent proposal by the Department of Justice (DOJ) to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) has sparked considerable discussion among investors in the burgeoning cannabis sector. As regulatory winds shift, investors are preparing for the potential impacts on market dynamics, investment strategies, and the overall landscape of cannabis-related businesses.